Amgen Discloses Material Cyber Breach: Proprietary Data and Patient Info Exfiltrated
AMGN sits 42% above its 52-week low of $269.77.
Summary
Amgen disclosed a material cybersecurity breach in an 8-K filing, revealing that proprietary data and protected patient health information were exfiltrated from a third-party cloud environment. The company deemed the incident material due to the volume and potential sensitivity of the files, though it stated no impact to products, financial reports, or manufacturing has been identified. This disclosure adds to a challenging period for Amgen, which is already navigating the potential U.S. withdrawal of Tavneos and a CFO transition. While Amgen does not currently expect a material financial impact, the breach raises significant concerns about data integrity, regulatory scrutiny, and potential litigation. The company's Q2 earnings are due after the market close on Tuesday, which may provide further clarity.
At the time of this announcement, AMGN was trading at $384.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.9B. The 52-week trading range was $269.77 to $398.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.